Pharmaceuticals and Medical News - July 22, 2026
Johnson & Johnson wins FDA approval for surgical robot Ottava, BridgeBio's drug receives FDA acceptance for rare genetic disorder ADH1, ImmuPharma partners with Thermo Fisher for diabetes drug candidate, and other pharmaceutical industry news
Johnson & Johnson has received FDA approval for its surgical robot Ottava, but details about the approval remain scarce.
BridgeBio has secured FDA acceptance of its new drug application for the treatment of ADH1, a rare genetic disorder, with a PDUFA date set for May 8, 2027. This marks an important milestone in the development of treatments for this condition.
ImmuPharma has partnered with Thermo Fisher to manufacture its diabetes drug candidate, using the latter's drug product CDMO for the Kapiglucagon program. This partnership should facilitate the production of the drug.
Other news in the pharmaceutical industry include Pfizer's partnership with Bluesight for source-tagged RFID medications in hospital pharmacies, a development that could improve medication tracking and efficiency in these settings.
While many details are still emerging, these announcements demonstrate ongoing innovation in the pharmaceutical sectors, from medical devices and treatments for rare conditions to improvements in medication distribution and production.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis